Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Editas Medicine (EDIT) Revenue (2016 - 2025)

Editas Medicine (EDIT) has disclosed Revenue for 11 consecutive years, with $7.5 million as the latest value for Q3 2025.

  • Quarterly Revenue rose 12265.57% to $7.5 million in Q3 2025 from the year-ago period, while the trailing twelve-month figure was $46.4 million through Sep 2025, down 24.9% year-over-year, with the annual reading at $32.3 million for FY2024, 58.64% down from the prior year.
  • Revenue for Q3 2025 was $7.5 million at Editas Medicine, up from $3.6 million in the prior quarter.
  • The five-year high for Revenue was $60.0 million in Q4 2023, with the low at $42000.0 in Q3 2022.
  • Average Revenue over 5 years is $9.0 million, with a median of $6.2 million recorded in 2021.
  • The sharpest move saw Revenue tumbled 99.32% in 2022, then surged 12604.76% in 2023.
  • Over 5 years, Revenue stood at $12.5 million in 2021, then plummeted by 47.58% to $6.5 million in 2022, then surged by 818.74% to $60.0 million in 2023, then tumbled by 49.03% to $30.6 million in 2024, then tumbled by 75.35% to $7.5 million in 2025.
  • According to Business Quant data, Revenue over the past three periods came in at $7.5 million, $3.6 million, and $4.7 million for Q3 2025, Q2 2025, and Q1 2025 respectively.